PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jclinpathJournal of Clinical PathologyVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
J Clin Pathol. 2007 September; 60(9): 1065–1066.
PMCID: PMC1972441

HDL‐cholesterol and triglycerides: an overlooked issue?

Several prospective clinical trials and epidemiological studies have shown that a low concentration of high‐density lipoprotein‐cholesterol (HDL‐C) is an independent risk factor for coronary heart disease (CHD).1,2 It is estimated that for every 0.0259 mmol/l decrease in HDL‐C, the relative risk of CHD events increases by 2–3%.3 Accordingly, HDL‐C determinations are included in CHD prevention programmes.4 Reliable and easy to perform HDL‐C assays are therefore required for routine laboratory practice.

There is often an inverse relationship between HDL‐C and triglyceride concentrations. Accordingly, specimens with a low HDL‐C often have a raised triglyceride concentration. HDL‐C assay manufacturers often recommend dilution when the triglyceride is above a particular concentration. We decided to evaluate our routine HDL‐C method to assess what triglyceride cut‐off we should routinely utilise before specimen dilution.

HDL‐C concentrations were determined using an anti human‐β‐lipoprotein antibody that binds to non‐HDL lipoproteins and allows the quantification of HDL‐C by the presence of a cholesterol esterase and cholesterol oxidase/peroxidase enzyme chromogen system (Olympus Life & Material Science Europa GmbH (Irish Branch)) on an Olympus AU600 analyser. Triglyceride was determined with a glycerolphosphate oxidase phenol‐aminophenazone method (Olympus Life & Material Science Europa) on an Olympus AU600 analyser. Both assays were performed according to the manufacturer's protocol. The manufacturer recommends that specimens are diluted with saline (no dilution factor stated) when the triglyceride concentration is >11.3 mmol/l. The setting of such a cut‐off implies that such procedure is acceptable in routine clinical practice—but our concern related to the stated value of 11.3 mmol/l. Serum samples from 35 fasted subjects giving a triglyceride concentration range from 0.47 mmol/l to 18.60 mmol/l (8, 7, 10 and 10 specimens having triglyceride concentrations of <2.5, 2.50–5.00, 5.01–11.30 and >11.30 mmol/l respectively) were obtained. Each specimen had HDL‐C measured using undiluted (range 0.51–2.57 mmol/l) and diluted serum. Specimens were manually diluted 1:3 with normal saline and the results were multiplied by 3. The percentage difference [(Neat − Diluted) × 100/Mean of Neat and Diluted] was assessed for each specimen. HDL‐C percentage difference plots were plotted according to specimen number (fig 1A1A)) and triglyceride concentration (fig 1B1B).). The National Cholesterol Education Programme (NCEP) and European objective total error (TE) criteria for HDL‐C of 8.9%5 and 11.1%6 respectively were included in these plots.

figure cp36988.f1
Figure 1 (A) Cumulative high‐density lipoprotein‐cholesterol (HDL‐C) percentage difference plot shows that of 35 specimens investigated, 7 had a lower 1:3 dilution compared to the neat and 7 had a higher 1:3 dilution compared ...

The plotting of the difference between the neat and the diluted specimens (fig 1B1B)) suggests a proportional systematic error in HDL‐C concentrations with increasing triglyceride concentrations, although the specimen with the triglyceride concentration of 18.6 mmol/l seems to be an outlier. Our data confirmed that the vast majority of specimens for HDL‐C analysis with triglyceride concentrations >11.3 mmol/l require dilution according to both the NCEP and the European objective TE criteria (table 1). However, 28% and 24% of the 25 specimens with triglyceride concentrations <11.3 mmol/l had differences greater than the NCEP and the European objective TE criteria respectively. In particular, 25% of the small number of specimens investigated (ie, 2 of 8) with a triglyceride concentration <2.5 mmol/l had TE greater than the criteria set down. All the undiluted specimens with triglyceride concentrations <11.3 mmol/l and significantly different HDL‐C concentrations on dilution with respect to the TE limits had lower values on dilution. More specifically, both specimens with triglycerides <2.5 mmol/l had differences greater than 20%.

Table thumbnail
Table 1 Percentage of specimens that were outside the National Cholesterol Education Programme (NCEP) and European total error (TE) limits according to triglyceride concentration

Knowledge of the HDL‐C concentration plays an important role in CHD risk estimation. Minimising false negatives is important in screening, and thus the TE criteria must be adhered to. As clinicians treat individuals, it is important that the TE criteria apply to the vast majority of patients. This is especially the case for those patients who are at increased risk of developing CHD—those with chronic kidney disease, diabetes mellitus, insulin resistance and abdominal obesity. In view of the heterogeneous nature of high density lipoproteins, it would not be unexpected if the specimen with the triglyceride of 18.6 mmol/l came from one of these patient groups. Not only may differences result in the underestimation of individual cardiovascular risk; the degree of the underestimation may be very significant as every 0.0259 mmol/l increase in HDL‐C is associated with a decrease in the relative risk for CHD events of 2–3%.3 Of the specimens with triglyceride concentration <2.5 mmol/l, two had differences greater than 20%, with the respective absolute differences being 0.46 mmol/l and 0.63 mmol/l. Thus, the use of neat specimens in those two examples may either be associated with underestimation of their relative risk for CHD events of the order of 36–54% and 48–72% respectively, or the use of diluted specimens overestimates the relative risk by a similar amount. Random non‐fasting specimens are advocated for screening purposes in the first instance in the United Kingdom.4 Accordingly, such random specimens are likely to have higher triglyceride concentrations compared to fasting and may be more prone to a negative HDL‐C bias.

It may be argued that pre‐dilution of the specimens invalidates the results. However, this procedure is in line with the European Union In Vitro Diagnostics Directive and CE (Conformité Europeanne) marking as per the manufacturers' instructions when the triglyceride concentration is >11.3 mmol/l. Furthermore, the specimen is diluted in any case with reagents in the reaction cuvette. The basis for the cut‐off point of 11.3 mmol/l is unclear. As all diluted sera had HDL‐C concentrations well above the assay limit of detection of 0.002 mmol/l provided by Olympus, imprecision is unlikely to be a major contributory factor to our results.

While confirming that dilution is essential when the triglyceride concentration is >11.3 mmol/l measured by our HDL‐C method, our small study also raises the possibility that in specimens with triglyceride concentrations <2.5 mmol/l there may be a significant difference between neat and diluted serum specimens for some patients. This raises questions about the robustness of HDL‐C for CHD estimation in a significant minority of patients. We believe that further investigation is required to confirm these findings, as the numbers in our study are small using all currently employed HDL‐C methodologies.

Footnotes

Competing interests: None declared.

References

1. NIH Consensus Development Panel on triglyceride, high density lipoprotein, and coronary heart disease. JAMA 1993. 269505–510.510 [PubMed]
2. Lewis B, Assmann G, Tikkanen M. et al Prevention of coronary heart disease: recommendations of the European Atherosclerosis Society, prepared by the International Task Force for Prevention of Coronary Heart Disease. Nutr Metab Cardiovasc Dis 1992. 2113–156.156
3. Gordon D J, Probstfield J L, Garrison R J. et al High density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989. 798–15.15 [PubMed]
4. JBS 2. Joint British Societies' guidelines on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, Stroke Association. Heart 2005. 91(Suppl 5)v1–52.52 [PMC free article] [PubMed]
5. Warnick G R, Wood P D. National Cholesterol Education Program recommendations for measurement of high‐density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin Chem 1995. 411427–1433.1433 [PubMed]
6. http://www.westgard.com/biodatabase1.htm (accessed 1 December 2005)

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Group